Gilmour Morrison

1.6k total citations · 2 hit papers
16 papers, 1.2k citations indexed

About

Gilmour Morrison is a scholar working on Pharmacology, Psychiatry and Mental health and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Gilmour Morrison has authored 16 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pharmacology, 13 papers in Psychiatry and Mental health and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Gilmour Morrison's work include Cannabis and Cannabinoid Research (13 papers), Epilepsy research and treatment (10 papers) and Pharmacological Effects and Toxicity Studies (6 papers). Gilmour Morrison is often cited by papers focused on Cannabis and Cannabinoid Research (13 papers), Epilepsy research and treatment (10 papers) and Pharmacological Effects and Toxicity Studies (6 papers). Gilmour Morrison collaborates with scholars based in United Kingdom, United States and Sweden. Gilmour Morrison's co-authors include Bola Tayo, Graham Blakey, Lesley Taylor, Julie C. Crockett, Barry E. Gidal, Kenneth W. Sommerville, David Critchley, Orrin Devinsky, Elizabeth A. Thiele and Kevan VanLandingham and has published in prestigious journals such as Neurology, Cancer Research and Epilepsia.

In The Last Decade

Gilmour Morrison

16 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

2018 341 citations Lesley Taylor, Barry E. Gidal et al. CNS Drugs profile →
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

2018 340 citations Orrin Devinsky, Anup D. Patel et al. Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gilmour Morrison United Kingdom	10	1.0k	436	297	184	170	16	1.2k
Daniel Checketts United Kingdom	17	1.2k 1.2×	922 2.1×	560 1.9×	369 2.0×	108 0.6×	29	1.7k
Bola Tayo United Kingdom	10	673 0.6×	167 0.4×	125 0.4×	88 0.5×	131 0.8×	12	750
Claire Roberts United Kingdom	8	731 0.7×	596 1.4×	369 1.2×	224 1.2×	60 0.4×	17	1.2k
Patricia L. Bruno United States	10	491 0.5×	469 1.1×	275 0.9×	192 1.0×	60 0.4×	14	884
Robert Flamini United States	12	496 0.5×	584 1.3×	323 1.1×	310 1.7×	50 0.3×	21	957
Divya Ramesh United States	17	1.2k 1.1×	88 0.2×	555 1.9×	76 0.4×	153 0.9×	34	1.4k
Alexandra L. Geffrey United States	7	438 0.4×	381 0.9×	227 0.8×	144 0.8×	44 0.3×	12	718
Martin Schnelle Germany	7	611 0.6×	67 0.2×	178 0.6×	82 0.4×	61 0.4×	8	818
Howard Rowe United States	16	458 0.4×	160 0.4×	250 0.8×	60 0.3×	124 0.7×	29	852
Andreas M. Stadelmann Germany	10	418 0.4×	62 0.1×	234 0.8×	48 0.3×	78 0.5×	14	668

Countries citing papers authored by Gilmour Morrison

Since Specialization

Citations

This map shows the geographic impact of Gilmour Morrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gilmour Morrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gilmour Morrison more than expected).

Fields of papers citing papers by Gilmour Morrison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gilmour Morrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gilmour Morrison. The network helps show where Gilmour Morrison may publish in the future.

Co-authorship network of co-authors of Gilmour Morrison

This figure shows the co-authorship network connecting the top 25 collaborators of Gilmour Morrison. A scholar is included among the top collaborators of Gilmour Morrison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gilmour Morrison. Gilmour Morrison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Ben‐Menachem, Elinor, Boudewijn Gunning, Carmen Cabrera, et al.. (2020). A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy. CNS Drugs. 34(6). 661–672. 37 indexed citations

VanLandingham, Kevan, Julie C. Crockett, Lesley Taylor, & Gilmour Morrison. (2020). A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam. The Journal of Clinical Pharmacology. 60(10). 1304–1313. 29 indexed citations

Devinsky, Orrin, Elizabeth A. Thiele, Stephen Wright, et al.. (2020). Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials. Acta Neurologica Scandinavica. 142(6). 531–540. 40 indexed citations

Patsalos, Philip N., Jerzy P. Szaflarski, Barry E. Gidal, et al.. (2020). Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. Epilepsia. 61(9). 1854–1868. 49 indexed citations

Crockett, Julie C., David Critchley, Bola Tayo, Joris Berwaerts, & Gilmour Morrison. (2020). A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects. Epilepsia. 61(2). 267–277. 59 indexed citations

Szaflarski, Jerzy P., et al.. (2019). Drug-drug Interaction (DDI) Studies with Coadministration of Cannabidiol (CBD) and Clobazam (CLB), Valproate (VPA), Stiripentol (STP) or Midazolam (MDZ) in Healthy Volunteers (HVTs) and Adults with Epilepsy (S3.003). Neurology. 92(15_supplement). 3 indexed citations

Tayo, Bola, Lesley Taylor, Farhad Sahebkar, & Gilmour Morrison. (2019). A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment. Clinical Pharmacokinetics. 59(6). 747–755. 46 indexed citations

Taylor, Lesley, Julie C. Crockett, Bola Tayo, & Gilmour Morrison. (2019). A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment. The Journal of Clinical Pharmacology. 59(8). 1110–1119. 83 indexed citations

Critchley, David, Jerzy P. Szaflarski, Philip N. Patsalos, et al.. (2019). Drug-drug Interaction Studies with Coadministration of Cannabidiol (CBD) and Clobazam, Valproate, Stiripentol or Midazolam in Healthy Volunteers and Adults with Epilepsy. Epilepsy & Behavior. 101. 106735–106735. 2 indexed citations

10.

Morrison, Gilmour, Julie C. Crockett, Graham Blakey, & Kenneth W. Sommerville. (2019). A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects. Clinical Pharmacology in Drug Development. 8(8). 1009–1031. 162 indexed citations

11.

Morrison, Gilmour, et al.. (2018). Exposure-Response Analysis of Cannabidiol (CBD) Oral Solution for the Treatment of Lennox–Gastaut Syndrome (P1.271). Neurology. 90(15_supplement). 1 indexed citations

12.

Taylor, Lesley, Barry E. Gidal, Graham Blakey, Bola Tayo, & Gilmour Morrison. (2018). A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. CNS Drugs. 32(11). 1053–1067. 341 indexed citations breakdown →

13.

Devinsky, Orrin, Anup D. Patel, Elizabeth A. Thiele, et al.. (2018). Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 90(14). e1204–e1211. 340 indexed citations breakdown →

14.

Patel, Anup D., Orrin Devinsky, Elizabeth A. Thiele, et al.. (2017). A dose ranging safety and pharmacokinetic study of cannabidol (CBD) in children with Dravet syndrome (GWPCARE1) (P4.108). Neurology. 88(16_supplement). 1 indexed citations

15.

Siu, Lillian L., Johann S. de Bono, Kari B. Wisinski, et al.. (2015). Abstract CT329: Phase I study of the PI3Kβ/δ inhibitor AZD8186 in patients with advanced castration resistant prostate cancer, triple negative breast cancer, squamous non-small cell lung cancer or PTEN deficient solid tumors: update from dose-finding. Cancer Research. 75(15_Supplement). CT329–CT329. 5 indexed citations

16.

Lewis, Craig, Elaine M. Rankin, Gilmour Morrison, et al.. (1990). Phase I and pharmacokinetic study of intraperitoneal thioTEPA in patients with ovarian cancer. Cancer Chemotherapy and Pharmacology. 26(4). 283–287. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact